Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), is now covered by Medicare and Medicaid. Approved by the Food and Drug Administration in April 2016, Inflectra is the first biosimilar indicated for the treatment of rheumatic and inflammatory diseases to come to market in the United States. The Centers for Medicare and Medicaid Services added it to its pricing list beginning January 1, 2017.
The Food and Drug Administration (FDA) has approved etanercept-szzs (brand name: Erelzi), a biosimilar form of etanercept (Enbrel), to treat rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis as well as plaque psoriasis. Earlier this year, infliximab-dyyb (Inflectra), a biosimilar version of infliximab (Remicade), became the first FDA-approved biosimilar for inflammatory types of arthritis in the U.S.
Continue reading FDA Approves Second Arthritis Biosimilar – Biosimilar Version of Drug Enbrel